Ameriprise Financial Inc. cut its holdings in shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 24.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,430,251 shares of the specialty pharmaceutical company’s stock after selling 464,816 shares during the quarter. Ameriprise Financial Inc. owned 2.56% of BioDelivery Sciences International worth $4,219,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Advisor Group Inc. lifted its holdings in BioDelivery Sciences International by 42.1% during the 2nd quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock worth $126,000 after buying an additional 13,341 shares in the last quarter. Stonepine Capital Management LLC increased its position in shares of BioDelivery Sciences International by 22.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 3,477,673 shares of the specialty pharmaceutical company’s stock valued at $9,737,000 after purchasing an additional 632,853 shares during the last quarter. GSA Capital Partners LLP increased its position in shares of BioDelivery Sciences International by 10.1% in the 2nd quarter. GSA Capital Partners LLP now owns 488,767 shares of the specialty pharmaceutical company’s stock valued at $1,369,000 after purchasing an additional 44,700 shares during the last quarter. EAM Investors LLC purchased a new stake in shares of BioDelivery Sciences International in the 2nd quarter valued at approximately $1,348,000. Finally, Northern Trust Corp increased its position in shares of BioDelivery Sciences International by 0.9% in the 2nd quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock valued at $394,000 after purchasing an additional 1,203 shares during the last quarter. Institutional investors own 44.08% of the company’s stock.

Shares of BioDelivery Sciences International, Inc. (BDSI) opened at $2.95 on Tuesday. BioDelivery Sciences International, Inc. has a 52-week low of $1.55 and a 52-week high of $3.60. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.28 and a quick ratio of 1.07. The company has a market cap of $164.86, a P/E ratio of -15.53 and a beta of 0.74.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.01. The firm had revenue of $11.25 million for the quarter, compared to the consensus estimate of $9.40 million. BioDelivery Sciences International had a net margin of 10.40% and a return on equity of 33.83%. The company’s revenue was up 215.1% on a year-over-year basis. During the same period last year, the firm posted ($0.30) EPS. equities research analysts anticipate that BioDelivery Sciences International, Inc. will post 0.16 earnings per share for the current year.

A number of equities research analysts have commented on BDSI shares. Roth Capital set a $5.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday, November 13th. Cantor Fitzgerald set a $5.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Thursday, October 12th. HC Wainwright started coverage on shares of BioDelivery Sciences International in a research report on Sunday, September 10th. They issued a “buy” rating and a $5.00 price objective on the stock. Finally, Piper Jaffray Companies set a $4.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Sunday, October 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. BioDelivery Sciences International has an average rating of “Buy” and a consensus price target of $4.29.

WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/01/02/ameriprise-financial-inc-trims-holdings-in-biodelivery-sciences-international-inc-bdsi.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Stock Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related stocks with our FREE daily email newsletter.